AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00941694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management intervention
Description: Intervention arm will receive 6 group or individual sessions over a 7 week period
Study NCT00941694 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: 3 phone calls not related to asthma self-management
Study NCT00540904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
Study NCT00540904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
Study NCT02554552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3ml
Description: phosphate buffered saline 3ml
Study NCT00931008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID530, Taxotere
Description: 75mg/m2
Study NCT01368107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
Study NCT01368107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
Study NCT01368107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin 7
Description: patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
Study NCT01368107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin 7
Description: patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
Study NCT01368107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interleukin 7
Description: patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
Study NCT00901784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25mg Tablets
Study NCT00931008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SID530, Taxotere
Description: 75mg/m2
Study NCT04363853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 MG/ML
Description: We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
Study NCT00979329 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
Study NCT03528109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
Study NCT03528109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
Study NCT01059526 — intervention group
Intervention type: DRUG
Intervention: ecallantide
Description: 30 mg SC
Study NCT01318538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Women's Recovery Group
Description: The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
Study NCT01318538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Drug Counseling
Description: Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
Study NCT02730000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART with Equia
Description: Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
Study NCT02730000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with Riva Self Cure
Description: Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
Study NCT03471897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glycosaminoglycan plasma score
Description: A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
Study NCT00901784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: 25mg Tablets
Study NCT00684632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00684632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246 (fentanyl citrate)
Description: KW-2246 (fentanyl citrate)
Study NCT05296200 — intervention group
Intervention type: DEVICE
Intervention: Hyperbuoyancy Floatation
Description: Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
Study NCT00382395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLX Gold Shunt GMS-plus
Description: Single use implant
Study NCT00382395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed FP7 Glaucoma Valve
Description: Single use implant
Study NCT02624505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg Reference Product
Description: Drug: 90 mcg Reference Product
Study NCT02624505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 180 mcg Reference Product
Description: Drug: 180 mcg of Reference Product
Study NCT02624505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg Test Product
Description: Drug: 90 mcg of Test Product
Study NCT02624505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study NCT06120114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified percutaneous internal ring suturing
Description: Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
Study NCT00718484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifosfamide Tris and Doxorubicin
Description: On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
Study NCT00718484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
Study NCT02484300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT02484300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04505202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Description: The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
Study NCT04505202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
Study NCT00463294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft with the use of CPB
Description: Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
Study NCT00463294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Graft without the use of CPB
Description: Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
Study NCT02993354 — intervention group
Intervention type: DEVICE
Intervention: The EUM300 (electrical uterine myography)
Description: This study involves monitoring one group of pregnant women for contractions simultaneously using two different devices to determine if one is superior: the usual tocodynamometer commonly used. Women are simultaneously monitored with both devices.
Study NCT03679468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: RehaCom software~Information processing speed and attention modules
Study NCT03679468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: RehaCom software~Information processing speed and attention modules
Study NCT03679468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Exercise
Description: Sets of balance and stretching exercises
Study NCT03679468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Rehabilitation
Description: Kompozer software~24 session module consisting of basic internet searches
Study NCT03679468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Recumbent NuStep Bike~Aerobic cycling
Study NCT03679468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic Exercise
Description: Recumbent NuStep Bike~Aerobic cycling
Study NCT00547183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Study NCT00547183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Study NCT00547183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
Study NCT02716857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone extended-release
Study NCT02716857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of oxycodone extended-release
Study NCT01593436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness training
Description: mindfulness interventions for 8 weeks for a group of menopausal insomniacs
Study NCT01086332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: 1250 mg twice daily
Study NCT01086332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
Study NCT02172950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Description: Recombinant single-chain coagulation factor VIII
Study NCT00496626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
Description: Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
Study NCT00496626 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
Study NCT03165578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
Study NCT03165578 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Feedback
Description: Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
Study NCT03442140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmonica playing
Description: Patients will play the harmonica for up to 6 months
Study NCT01487902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
Study NCT01487902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No ADT
Description: Docetaxel-prednisolone (TAX327 regimen) alone
Study NCT02795715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT02795715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Study NCT02795715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Study NCT02795715 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Study NCT01525641 — intervention group
Intervention type: DRUG
Intervention: Mirapex LA
Description: Pramipexole Hydrochloride Hydrate
Study NCT00210964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole plus placebo
Description: ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
Study NCT00210964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid plus ceftazidime
Description: linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
Study NCT00582959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cone Beam Imaging
Description: Prototype, third generation EPID based portal imaging system utilizing the MV approach.
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV and orally
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00392886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00392886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Given on day 0
Study NCT00392886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Given on day 0
Study NCT00392886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Given on day 0
Study NCT00392886 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
Study NCT03781947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA
Description: A single s.c. or i.m. injection of teverelix TFA administered on Day 1
Study NCT01193062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
Study NCT01193062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
Study NCT00607256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-reboxetine
Description: S_S reboxetine dosed daily.
Study NCT03220165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: oral, 100 mg
Study NCT01792323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO
Description: Administration of 15 IU of insulin lispro over a period of 30 seconds
Study NCT01186380 — intervention group
Intervention type: DEVICE
Intervention: PET-512MC
Description: Transesophageal Transducer
Study NCT02393430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide is a
Study NCT02393430 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: optimization of life style
Study NCT02393430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: optimization of life style
Study NCT04399603 — intervention group
Intervention type: OTHER
Intervention: no intervention-mechanistic study
Description: no intervention-mechanistic study
Study NCT00345878 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT00345878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 VLP AS04 (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT00477997 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Bolus of Growth Hormone
Description: 0,5 mg Norditropin
Study NCT00477997 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Physiological Bolus of Growth Hormone
Description: 0,5 mg Norditropin
Study NCT02696447 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biomarkers assays
Description: D-Dimer assays, C-reactive protein, blood platelets assays
Study NCT00718796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise
Description: Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
Study NCT00718796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)
Description: Will vary according to individual - not standardized and likely to include statins.
Study NCT00871442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Basal Infusion
Description: Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
Study NCT00871442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal infusion
Description: Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)